The Therapeutic Effect of Menatetrenone (Vitamin K2) on Posttransplant Osteoporosis in Renal Transplant Recipient.
- Author:
Jin A PARK
1
;
Mi Jeong SIN
;
Youn Joo JOEN
;
Seong Yong WOO
;
Jung Min YOON
;
Bum Soon CHOI
;
Chul Woo YANG
;
Yong Soo KIM
;
Suk Young KIM
;
Yoon Sik CHANG
;
Byung Kee BANG
Author Information
1. Department of Internal Medicine, Kangnam St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. yangch@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Vitamin K2 (Menatetrenone(R));
Vitamin D3;
Posttransplant osteoporosis;
DEXA
- MeSH:
Absorptiometry, Photon;
Calcium Carbonate;
Cholecalciferol;
Female;
Femur Neck;
Follow-Up Studies;
Humans;
Male;
Metabolism;
Osteoporosis*;
Prospective Studies;
Spine;
Transplantation*;
Vitamin K 2
- From:Korean Journal of Nephrology
2004;23(6):934-941
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Posttransplant osteoporosis in renal transplant recipient is frequently observed complications, but therapeutic modalities are not clearly elucidated. Recent studies indicate that vitamin K2 also play a role in bone metabolism. Therefore, we performed prospective study to evaluate the effect of vitamin K2 (Menatetrenone(R)) on posttransplant osteroporosis. METHODS: Our study included total 83 patients (40 male, 43 female; age 36.9+/-5.5 years) who received a renal transplant more than 6 months ago. They underwent dual-energy X-ray absorptiometry (DEXA) at lumbar spine and femoral neck. The patients with osteoporosis were treated with vitamin K2 (glakay 15 mg) (group 1) or vitamin D3 with calcium carbonate (group 2). The patients without osteoporosis was observed without any treatment (group 3). After one year, follow-up BMD was performed in all patients. RESULTS: Of 83 patients, 44 patients (53.0%) had osteoporosis and 39 patients (47.0%) had not. In group 1 (N=28), vitamin K2 treatment significantly increased BMD at femoral neck (-3.2+/-0.4 vs 2.6+/-0.6, p<0.05), but there was no increase of BMD at lumbar spine (-2.2+/-1.0 vs 2.2+/-0.9, p>0.05). In group 2 (N=16), there was significant increase in BMD at femoral neck (-3.0+/-0.6 vs -2.5+/-0.8, p< 0.05), but there was no increase of BMD at lumbar spine (-1.8+/-0.7 vs -1.8+/-0.8, p>0.05). Between group 1 and 2, there was no significant difference in BMD change. In group 3, BMD decreased at femoral neck (-1.3+/-0.2 vs -1.5+/-0.2) and lumbar spine (-0.8+/-0.2 vs -1.0+/-0.2) during follow-up period. CONCLUSION: Vitamin K2 (Menatetrenone(R)) is effective in treating osteoporosis at femoral neck and its effectiveness is s imilar with that of using vitamin D3 with calcium carbonate.
